Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.75 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.75 |
| ▸ | STAT3 | P40763 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.68 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 3/20 | 0.56 |
| ▸ | BRD4 | O60885 | 3/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23702529 | 0.97 | CRBN (0.74) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL29622144 | 0.97 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL29622167 | 0.97 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL22326312 | 0.97 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL24765180 | 0.97 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL27267629 | 0.97 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL24376929 | 0.97 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL24558580 | 0.97 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL29622191 | 0.95 | CRBN (0.78) | CRBNDDB1STAT3HDAC1HDAC6 | |
| SCHEMBL24376595 | 0.95 | CRBN (0.78) | CRBNDDB1STAT3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116867-A1 | PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 | ST JUDE CHILDRENS RES HOSPITAL (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | CELGENE CORPORATION (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4562012-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026256-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026256-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230391765-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-12-07 | — | — | US | disclosed |
| WO-2023205807-A2 | PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | UPPTHERA (KR) | 2021-07-20 | — | — | US | disclosed |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | UPPTHERA (KR) | 2021-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391765-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | MLLT1, BCR, MCL1 | CRBN 11/4885DDB1 668/4885STAT3 1149/4885 |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | IRAK3, IRAK2, IRAK1 | CRBN 35/4885DDB1 1089/4885STAT3 27/4885 |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | HMGCR, LDLR, HMGB2 | CRBN 1054/4885DDB1 441/4885STAT3 4491/4885 |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | CRBN 500/4885DDB1 1650/4885STAT3 1294/4885 |
| US-20260116867-A1 | PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 | NR3C1, GPER1, NR1H4 | CRBN 1192/4885DDB1 860/4885STAT3 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.